PharmGenScience Registers Patent On Innovative New Drug Giant Ring-Type Hepatic-Specific MRI Contrast Agent
Jul 15, 2025
FarmGenScience (CEO Park Hee-deok, Kim Hye-yeon) announced on the 15th that its giant ring-shaped liver-specific magnetic resonance imaging (MRI) contrast medium (RD1303), an innovative new drug candidate being developed, has completed patent registration in China.
Based on RD1303's superior chemical stability and hepatocellularity structure, FarmGenScience has applied for patents in seven countries (US, China, Japan, Europe, Australia, Canada, and Brazil), including South Korea. Registration has been completed in four countries, including China, Korea, Australia, and Japan.
RD1303 is being developed as a Gadolinium (Gd)-based giant ring structure. It is selectively absorbed into hepatocytes via specific transporters within the hepatocyte membrane. It provides excellent signal-to-noise ratio (SNR) between the lesion and normal liver tissue, which is advantageous for precise diagnosis such as early liver cancer (HCC).
In particular, the macroscopic ring structure minimizes the possibility of separation between gadolinium and the transporter, facilitating extracorporeal discharge after functioning as a contrast medium. It is distinguished from conventional linear contrast agents, which are of great concern for fatal systemic side effects caused by the residual of gadolinium ions in the body.
FarmGenScience's giant ring-shaped liver-specific MRI contrast medium has been consecutively selected for the national new drug development project in 2022 and 2024. Currently, non-clinical research is actively underway.
A FarmGenScience official said, "During the increasing demand for high-precision imaging diagnosis, liver-specific contrast agents are a key technology that will lower the entry barrier for precision medicine and lead to standardization of patient-specific diagnosis in the future."," he said.
Based on RD1303's superior chemical stability and hepatocellularity structure, FarmGenScience has applied for patents in seven countries (US, China, Japan, Europe, Australia, Canada, and Brazil), including South Korea. Registration has been completed in four countries, including China, Korea, Australia, and Japan.
RD1303 is being developed as a Gadolinium (Gd)-based giant ring structure. It is selectively absorbed into hepatocytes via specific transporters within the hepatocyte membrane. It provides excellent signal-to-noise ratio (SNR) between the lesion and normal liver tissue, which is advantageous for precise diagnosis such as early liver cancer (HCC).
In particular, the macroscopic ring structure minimizes the possibility of separation between gadolinium and the transporter, facilitating extracorporeal discharge after functioning as a contrast medium. It is distinguished from conventional linear contrast agents, which are of great concern for fatal systemic side effects caused by the residual of gadolinium ions in the body.
FarmGenScience's giant ring-shaped liver-specific MRI contrast medium has been consecutively selected for the national new drug development project in 2022 and 2024. Currently, non-clinical research is actively underway.
A FarmGenScience official said, "During the increasing demand for high-precision imaging diagnosis, liver-specific contrast agents are a key technology that will lower the entry barrier for precision medicine and lead to standardization of patient-specific diagnosis in the future."," he said.
|
This article was translated by Naver AI translator.
